BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

A nonprofit dedicated to improving vaccination rates to eradicate meningococcal meningitis is brightening things up this ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculate | This ...

On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American ...

Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

For the biotech formerly known as Eliem Therapeutics, it’s all about the climb—Climb Bio, that is. | For the biotech formerly ...

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly ...